California State Teachers Retirement System Sells 34,344 Shares of Edwards Lifesciences Corporation $EW

California State Teachers Retirement System lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 3.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 871,700 shares of the medical research company’s stock after selling 34,344 shares during the quarter. California State Teachers Retirement System’s holdings in Edwards Lifesciences were worth $69,806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Viking Global Investors LP bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $238,688,000. Marshall Wace LLP lifted its stake in Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after acquiring an additional 2,359,128 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Edwards Lifesciences by 341.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,890,859 shares of the medical research company’s stock valued at $151,420,000 after acquiring an additional 1,462,238 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Truist Financial lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Citigroup lifted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 44,558 shares of company stock worth $3,770,939 over the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Up 1.4%

Shares of EW stock opened at $87.00 on Friday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The firm has a fifty day moving average price of $87.91 and a 200-day moving average price of $83.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market cap of $50.10 billion, a price-to-earnings ratio of 50.00, a PEG ratio of 2.15 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the business posted $0.67 EPS. Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.